No profile data available.
Iqvia Holdings Inc. (IQV) is a healthcare company in the trial phase contract research industry, based in Durham, United States, with about 94,000 full-time employees.
It reported revenue of $16.31 billion for fiscal year 2025, and net income of $1.36 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $4.37 billion. Its largest business segment, Research & Development Solutions, brought in 55% of segment revenue in fiscal year 2025; United States was the largest region with 42%. Its market capitalization was $42.78 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Iqvia reported $16.31 billion in revenue for fiscal year 2025. In Q2 2026 revenue was $4.37 billion.
Research & Development Solutions, with $8.90 billion or 55% of segment revenue in fiscal year 2025. Next: Commercial Solutions (41%) and Contract Sales & Medical Solutions (5%).
United States: 42% of revenue by region in fiscal year 2025, followed by Europe and Africa (32%).
$42.78 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (trial phase contract research) include Medpace Holdings, Inc. (MEDP), Fortrea Holdings Inc. (FTRE), Cannabis Bioscience International Holdings, Inc. (CBIH).